Medpace Holdings, Inc. (MEDP)
NASDAQ: MEDP · Real-Time Price · USD
582.48
-10.59 (-1.79%)
At close: Jan 30, 2026, 4:00 PM EST
578.50
-3.98 (-0.68%)
After-hours: Jan 30, 2026, 7:28 PM EST
Medpace Holdings Revenue
Medpace Holdings had revenue of $659.90M in the quarter ending September 30, 2025, with 23.74% growth. This brings the company's revenue in the last twelve months to $2.36B, up 13.88% year-over-year. In the year 2024, Medpace Holdings had annual revenue of $2.11B with 11.84% growth.
Revenue (ttm)
$2.36B
Revenue Growth
+13.88%
P/S Ratio
7.29
Revenue / Employee
$399,724
Employees
5,900
Market Cap
16.41B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.11B | 223.21M | 11.84% |
| Dec 31, 2023 | 1.89B | 425.85M | 29.17% |
| Dec 31, 2022 | 1.46B | 317.62M | 27.80% |
| Dec 31, 2021 | 1.14B | 216.45M | 23.38% |
| Dec 31, 2020 | 925.93M | 64.96M | 7.54% |
| Dec 31, 2019 | 860.97M | 156.38M | 22.19% |
| Dec 31, 2018 | 704.59M | 268.44M | 61.55% |
| Dec 31, 2017 | 436.15M | 14.57M | 3.46% |
| Dec 31, 2016 | 421.58M | 62.52M | 17.41% |
| Dec 31, 2015 | 359.06M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Labcorp Holdings | 13.77B |
| Quest Diagnostics | 10.85B |
| ICON Public Limited Company | 8.10B |
| Illumina | 4.29B |
| Charles River Laboratories International | 4.02B |
| Mettler-Toledo International | 3.94B |
| Waters | 3.11B |
| Exact Sciences | 3.08B |
MEDP News
- 26 days ago - Medpace Holdings, Inc. to Report Fourth Quarter and Fiscal Year 2025 Financial Results on February 9, 2026 - Business Wire
- 2 months ago - Wasatch Global Opportunities Fund Q3 2025 Contributors And Detractors - Seeking Alpha
- 2 months ago - 6 Healthcare Stocks With Strong Upward Momentum - Benzinga
- 3 months ago - Medpace Analysts Increase Their Forecasts After Upbeat Q3 Earnings - Benzinga
- 3 months ago - Medpace: Full CRO Model Builds Net Revenue Growth, Maintain At Strong Buy - Seeking Alpha
- 3 months ago - Medpace Holdings, Inc. (MEDP) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 months ago - Medpace's Q3 Earnings Beat Reflects Robust Growth And Large New Wins - Benzinga
- 3 months ago - Medpace Holdings' Good Quarter Is Another Sign Biotech Is Back - Barrons